WO2003084503A3 - P38 kinase inhibitors for treating mucus hypersecretion_ - Google Patents

P38 kinase inhibitors for treating mucus hypersecretion_ Download PDF

Info

Publication number
WO2003084503A3
WO2003084503A3 PCT/EP2003/003434 EP0303434W WO03084503A3 WO 2003084503 A3 WO2003084503 A3 WO 2003084503A3 EP 0303434 W EP0303434 W EP 0303434W WO 03084503 A3 WO03084503 A3 WO 03084503A3
Authority
WO
WIPO (PCT)
Prior art keywords
kinase inhibitors
mucus hypersecretion
treating mucus
treating
inhalation
Prior art date
Application number
PCT/EP2003/003434
Other languages
French (fr)
Other versions
WO2003084503A2 (en
Inventor
Birgit Jung
Original Assignee
Boehringer Ingelheim Pharma
Birgit Jung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Birgit Jung filed Critical Boehringer Ingelheim Pharma
Priority to EP03720407A priority Critical patent/EP1494645A2/en
Priority to IL16373703A priority patent/IL163737A0/en
Priority to AU2003224025A priority patent/AU2003224025A1/en
Priority to CA002479520A priority patent/CA2479520A1/en
Priority to JP2003581743A priority patent/JP2005528374A/en
Priority to KR10-2004-7015891A priority patent/KR20040101398A/en
Priority to MXPA04009605A priority patent/MXPA04009605A/en
Priority to BR0309009-4A priority patent/BR0309009A/en
Priority to NZ536278A priority patent/NZ536278A/en
Publication of WO2003084503A2 publication Critical patent/WO2003084503A2/en
Publication of WO2003084503A3 publication Critical patent/WO2003084503A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention relates to the use of p38 kinase inhibitors for the preparation of a pharmaceutical composition suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compositions suitable for inhalation comprising p38 kinase inhibitors and to methods for the preparation thereof.
PCT/EP2003/003434 2002-04-05 2003-04-02 P38 kinase inhibitors for treating mucus hypersecretion_ WO2003084503A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP03720407A EP1494645A2 (en) 2002-04-05 2003-04-02 Method of treating mucus hypersecretion
IL16373703A IL163737A0 (en) 2002-04-05 2003-04-02 Method of treating mucus hypersecretion
AU2003224025A AU2003224025A1 (en) 2002-04-05 2003-04-02 p38 kinase inhibitors for treating mucus hypersecretion
CA002479520A CA2479520A1 (en) 2002-04-05 2003-04-02 P38 kinase inhibitors for treating mucus hypersecretion_
JP2003581743A JP2005528374A (en) 2002-04-05 2003-04-02 How to treat mucus hypersecretion
KR10-2004-7015891A KR20040101398A (en) 2002-04-05 2003-04-02 Method of treating mucus hypersecretion
MXPA04009605A MXPA04009605A (en) 2002-04-05 2003-04-02 Method of treating mucus hypersecretion.
BR0309009-4A BR0309009A (en) 2002-04-05 2003-04-02 Method for the treatment of mucus hypersecretion
NZ536278A NZ536278A (en) 2002-04-05 2003-04-02 p38 kinase inhibitors for treating mucus hypersecretion associated with cystic fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007699.8 2002-04-05
EP02007699 2002-04-05

Publications (2)

Publication Number Publication Date
WO2003084503A2 WO2003084503A2 (en) 2003-10-16
WO2003084503A3 true WO2003084503A3 (en) 2004-04-08

Family

ID=28685842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003434 WO2003084503A2 (en) 2002-04-05 2003-04-02 P38 kinase inhibitors for treating mucus hypersecretion_

Country Status (14)

Country Link
EP (1) EP1494645A2 (en)
JP (1) JP2005528374A (en)
KR (1) KR20040101398A (en)
CN (1) CN1658834A (en)
AU (1) AU2003224025A1 (en)
BR (1) BR0309009A (en)
CA (1) CA2479520A1 (en)
IL (1) IL163737A0 (en)
MX (1) MXPA04009605A (en)
NZ (1) NZ536278A (en)
PL (1) PL372963A1 (en)
RU (1) RU2004132847A (en)
WO (1) WO2003084503A2 (en)
ZA (1) ZA200406910B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101529A1 (en) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and medical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006137421A1 (en) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent for topical administration
FR2903774B1 (en) * 2006-07-17 2008-09-05 Renault Sas METHOD FOR VALIDATING A FUNCTIONING DIAGNOSTIC OF A DEVICE.
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
AU2009326148B2 (en) 2008-12-11 2014-05-08 Respivert Limited p38 MAP kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (en) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055139A2 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
WO2000071535A1 (en) * 1999-05-21 2000-11-30 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
WO2001012609A1 (en) * 1999-08-19 2001-02-22 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
WO2001019322A2 (en) * 1999-09-17 2001-03-22 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
US6277989B1 (en) * 1998-08-28 2001-08-21 Scios, Inc. Quinazoline derivatives as medicaments
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002032862A2 (en) * 2000-10-19 2002-04-25 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of smoke inhalation
WO2002083642A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2003041644A2 (en) * 2001-11-09 2003-05-22 Scios Inc. Method to treat cystic fibrosis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277989B1 (en) * 1998-08-28 2001-08-21 Scios, Inc. Quinazoline derivatives as medicaments
WO2000055139A2 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
WO2000071535A1 (en) * 1999-05-21 2000-11-30 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
WO2001012609A1 (en) * 1999-08-19 2001-02-22 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
WO2001019322A2 (en) * 1999-09-17 2001-03-22 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
WO2002022601A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002032862A2 (en) * 2000-10-19 2002-04-25 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of smoke inhalation
WO2002083642A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2003041644A2 (en) * 2001-11-09 2003-05-22 Scios Inc. Method to treat cystic fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHAGOO STEPHEN B ET AL: "Cystic Fibrosis pathogens potentiate the bradykinin-induced interleukin-8 production from human lung fibroblasts.", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), Annual Meeting of the Professional Research Scientists on Experimental Biology;New Orleans, Louisiana, USA; April 20-24, 2002, March 20, 2002, pages A592, XP009014090, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
KR20040101398A (en) 2004-12-02
ZA200406910B (en) 2006-06-28
WO2003084503A2 (en) 2003-10-16
EP1494645A2 (en) 2005-01-12
BR0309009A (en) 2005-03-22
CN1658834A (en) 2005-08-24
IL163737A0 (en) 2005-12-18
PL372963A1 (en) 2005-08-08
NZ536278A (en) 2007-05-31
AU2003224025A1 (en) 2003-10-20
JP2005528374A (en) 2005-09-22
MXPA04009605A (en) 2005-01-11
RU2004132847A (en) 2006-08-20
CA2479520A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
GB0112348D0 (en) Compounds
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
WO2005013914A3 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
WO2004037773A8 (en) Phenethanolamine derivative for the treatment of respiratory diseases
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
HUP0304045A3 (en) Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them
WO2003084503A3 (en) P38 kinase inhibitors for treating mucus hypersecretion_
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
MXPA04005809A (en) Protein kinase inhibitors.
WO2002064160A8 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2005082884A3 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease
WO2004004725A3 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
AU2002231283A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501559

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003720407

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 163737

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004/06910

Country of ref document: ZA

Ref document number: 200406910

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2579/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2479520

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003224025

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009605

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047015891

Country of ref document: KR

Ref document number: 2003581743

Country of ref document: JP

Ref document number: 372963

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 536278

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004132847

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047015891

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038129884

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003720407

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2003720407

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003720407

Country of ref document: EP